Synvisc and Synvisc–One®

  • Evidence is also available in Portable Document Format (PDF)

Synvisc and Synvisc–One®

Hyaluronic acid is a naturally occurring substance within the synovial fluid of a joint that acts as a shock absorber, lubricant, and anti–inflammatory agent. Synvisc and Synvisc–One® (hylan G–F 20) are synthetic intra–articular hyaluronic acid injections intended to treat the pain and limitation of motion associated with osteoarthritis of the knee.

The New York State Department of Health will make a determination whether or not to add coverage of Synvisc and Synvisc–One for treatment of osteoarthritis of the knee to the Medicaid benefit package.

Dossier sources of evidence already submitted:

The following evidence was recently submitted to the Department:

  1. Altman R, Fredericso M, Bhattacharyya SK, et al. Association between hyaluronic acid injections and time–to–total knee replacement surgery. J Knee Surg 2015; ePub 12/08/2015.
  2. Altman R, Lim S, Steen RG, Dasa V. Hyaluronic Acid Injections Are Associated with Delay of Total Knee Replacement Surgery in Patients with Knee Osteoarthritis: Evidence from a Large U.S. Health Claims Database. PLoS One. 2015;10(12):e0145776.
  3. Band PA, Heeter J, Wisniewski HG, et al. Hyaluronan molecular weight distribution is associated with the risk of knee osteoarthritis progression. Osteoarthritis Cartilage. Jan 2015;23(1):70–76.
  4. Bannuru RR, McAlindon TE, Sullivan MC, et al. Effectiveness and Implications of Alternative Placebo Treatments: A Systematic Review and Network Meta–analysis of Osteoarthritis Trials. Ann Intern Med. Sep 1 2015;163(5):365–372.
  5. Bannuru RR, Natov NS, Dasi UR, et al. Therapeutic trajectory following intra–articular hyaluronic acid injection in knee osteoarthritis–meta–analysis. Osteoarthritis and Cartilage. 2011;19:611e619
  6. Chevalier X, Jerosch J, Goupille P, et al. Single, intra–articular treatment with 6 ml hylan GF 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double–blind, placebo controlled trial. Ann Rheum Dis. Jan 2010;69(1):113–119.
  7. Newberry SJ, FitzGerald J, Maglione MA, et al. Systematic Review for Effectiveness of Hyaluronic Acid in the Treatment of Severe Degenerative Joint Disease (DJD) of the Knee. (Prepared by the Southern California Evidence–based Practice Center under Contract No. HHSA290201200006I.) Rockville, MD: Agency for Healthcare Research and Quality. July 23, 2015.
  8. Ong KL, Anderson AF, Niazi F, et al. Hyaluronic Acid Injections in Medicare Knee Osteoarthritis Patients Are Associated With Longer Time to Knee Arthroplasty. J Arthroplasty. Jan 29 2016.
  9. Petrella RJ, Wakeford C. Pain relief and improved physical function in knee osteoarthritis patients receiving ongoing hylan G–F 20, a high–molecular–weight hyaluronan, versus other treatment options: data from a large real–world longitudinal cohort in Canada. Drug Des Devel Ther. 2015;9:5633–5640.
  10. Trojian TH, Concoff AL, Joy SM, et al. AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis: Importance for Individual Patient Outcomes. Clin J Sport Med. Jan 2016;26(1):1–11.
  11. Waddell DD, Joseph B. Delayed Total Knee Replacement with Hylan G–F 20. J Knee Surg. Feb 2016;29(2):159–168.
  12. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G–F 20: a 26–week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. May–Jun 1998;20(3):410–423.
  13. American Academy of Orthopaedic Surgeons. Treatment of Osteoarthritis of the knee.
    Summary of Recommendations. 2013.
    http://www.aaos.org/research/guidelines/OAKSummaryofRecommendations.pdf.
    Accessed February 27, 2013.